introduction to instantaneous wave-free ratio€¦ · define flair clinical endpoints study...

49
Alejandro Aquino MD Interventional Cardiology Fellow Washington University in St. Louis Barnes-Jewish Hospital Instantaneous Wave-Free Ratio

Upload: lydat

Post on 04-Sep-2018

222 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

Alejandro Aquino MD

Interventional Cardiology Fellow

Washington University in St. Louis

Barnes-Jewish Hospital

Instantaneous

Wave-Free Ratio

Page 2: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

Alejandro Aquino MD

Disclosure

No disclosures

Instantaneous Wave-Free Ratio

Page 3: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

Outline

• iFR Basics

• iFR Data

• Future Directions

• Wash U Experience

• Cases - Caveats

Page 4: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

Physiologic Assessment of CAD

• Basis of FFR modality linear relationship between

pressure and flow under constant and minimized

coronary resistance1

• Under these conditions, changes in pressure across

a stenosis can be a surrogate for blood flow to

myocardium

P = Q x R Pressure = Flow x Resistance

1) Spaan JA. Physiologic basis of clinically used coronary hemodynamic indices. Circulation 2006.

or ∆P = ∆Q x R Change in Pressure = Change in Flow

x Constant Resistance

Page 5: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

Intracoronary Resistance

• Intracoronary resistance fluctuates in a phasic pattern

• Reflects interaction between myocardium and

microvasculature

High Intracoronary resistance

Microvasculature compression

Low Intracoronary resistance

Microvasculature

decompression

Systole Diastole

P =Q x R Pressure = Flow x Resistance

Page 6: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

FFR

HYPEREMIA

• Minimizing IC resistance during measurement of FFR • Calculated during hyperemia (adenosine)

• Average over several cycles

P =Q x R Pressure = Flow x Resistance

Page 7: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

Do we need adenosine?

• Contraindicated or disliked by patients

• Adds to procedural time

• Adds to procedural costs

Davies J. Primary Results of ADVISE. TCT 2011.

Page 8: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

Can a time of naturally occurring stable

resistance be identified?

Page 9: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

iFR

• Instantaneous pressure ratio across a stenosis during

the wave-free period, when resistance is naturally

constant and minimized in the cardiac cycle

Davies J. Primary Results of ADVISE. TCT 2011.

Wave Free Period

Pd/Pa

P =Q x R Pressure = Flow x Resistance

Page 10: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

Development of iFR

• Development and Validation of a New Adenosine-Independent

Index of Stenosis Severity From Coronary Wave–Intensity Analysis:

Results of the ADVISE (ADenosine Vasodilator Independent Stenosis

Evaluation) Study

J Am Coll Cardiol. 2012;59(15):1392-1402.

Tested

hypothesis by

comparing iFR

with FFR

measurements

Identify diastolic

interval in which

IC resistance is

equal to time-

averaged

resistance during

FFR

PROOF OF CONCEPT

Page 11: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

Resistance During the Wave Free Period

Within a defined diastolic wave-free period, resting coronary

resistance was similar to that seen during adenosine-mediated FFR

Page 12: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

Correlation between iFR and FFR

iFR correlates closely with FFR in all coronary arteries

Page 13: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

AUC = 93%

Diagnostic accuracy of iFR as compared to

FFR cutoff value of 0.8

Page 14: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

VERIFY

• Prospective, multicenter study of 206 consecutive pts

referred for PCI and 500 archived pressure recordings

• Excluded h/o CABG, extreme tortuosity, severe calcification,

MI w/in 5 days

• Diagnostic Performance of iFR 0.83 vs FFR 0.80

Page 15: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

VERIFY

• iFR did change during hyperemia

• 0.82 ± 0.16 0.64 ± 0.18

• ROC

• iFR similar to resting Pd/Pa and

trans-stenotic pressure gradient

Page 16: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

iFR vs FFR

Page 17: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

ADVISE Registry

• Evaluated the relationship between iFR and FFR in pts

with intermediate lesions

• Lesions where functional assessment is clinically relevant and in

agreement with guidelines

• 312 pts with 339 coronary stenoses

• AUC 0.86

• Identified optimal

iFR cutoff value of

0.89 to match

FFR value of 0.8

Page 18: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

ADVISE Registry Agreement between

Repeated Measurement of

FFR

Agreement between iFR

and FFR

Overall

classification

agreement of 85%

Overall

classification

agreement of 8o%

Taking into account the FFR repeatability (85%), iFR/FFR

agreement was 94% for classifying lesions as

significant/insignificant

Page 19: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

Hybrid iFR-FFR Approach • Hybrid iFR-FFR decision-making strategy: implications for

enhancing universal adoption of physiology-guided coronary

revascularisation (Euro Intervention, Dec 2012)

Page 20: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

ADVISE II

• Prospective, observational, nonrandomized, double blind, global, multi-center

registry

• iFR value to characterize coronary stenosis as determined by FFR

• n=797 patients evaluated

1) 94.0% match to FFR

2) 65.1% of patients may be free from hyperemic agents

Page 21: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

DEFINE FLAIR Clinical Endpoints

Study Objectives:

• Determine safety and efficacy of PCI-

guided iFR vs. FFR

• Determine if iFR is non-inferior to FFR

to guide PCI

Primary Endpoints:

• Major adverse cardiac events (MACE)

rate in the iFR and FFR groups at 1

year

• MACE (combined endpoint of death,

non-fatal MI, or unplanned

revascularization)

Largest Physiology Study to

Date

• n=2500

• 51 Sites, 17 countries

Page 22: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

Summary Slide

• ADVISE

• Proof of Concept

• ADVISE Registry

• Intermediate Lesions

• Overall good agreement

• Less so around cutoff points

• Hybrid iFR-FFR

• Introduced concept

• ADVISE II

• Hybrid approach tested prospectively

• DEFINE FLAIR

• Ongoing

• Testing clinical endpoints

• VERIFY

Page 23: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

Wash U Experience • Prospective, observational study

• 46 consecutive lesions at BJH Cathlab

• 44 lesions with both FFR and iFR performed

• Mean age 65 ± 8 years

• 26% with diabetes

• All vessels, ostial, proximal, mid and distal lesions

0

.25

.5.7

5

1

Sen

sitiv

ity

0 .25 .5 .75 11 - Specificity

Area under curve = 0.9157, 95%CI 0.83 to 0.99

Diagnostic Accuracy of iFR

Best Cut-point iFR =

0.91

Sensitivity = 86%

Specificity = 86%

Page 24: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

Conclusions – Part 1 • iFR has good correlation with FFR

• High correlation coefficient

• High area under the ROC curve

• Correctly classifies 86% of lesions

• It thus appears to be reasonably reliable in assessing

the functional significance of intermediate lesions

• Recognize the gray zone between 0.86 – 0.93

• May be used in routine clinical practice, saving time

and money

Page 25: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

Cases

Page 26: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

26

1 2

FIO2 & Hct (or Hb) Arterial

Lilly, L. Pathophysiology of Heart Disease. Lippincott, 2007. 4th ed..

Page 27: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

Coronary Reserve

Page 28: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

History of Present Illness

63yo gentleman with a history of CAD with prior

PCI and ischemic cardiomyopathy.

Presents with 2-3 weeks of worsening chest

tightness and dyspnea with exertion.

Given rapid progression of symptoms over the last week he is referred for L heart catheterization.

Page 29: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

Past Medical History

• CAD:

• Promus Element 3.5 x 20mm and 2.5 x 16mm stents placed in

LAD/2nd diagonal bifurcation in 2012

• Promus Element 2.5x28 and 2.5x20 placed in mid LCx in 2012

• Ischemic cardiomyopathy

• EF 25-30% since 2012

• Status post ICD for primary prevention

• HTN

• HLD

• Former tobacco use

Page 30: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

Patent Stents

Page 31: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

RCA

Page 32: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

IFR/FFR Analysis of RCA Lesion

• 6 French JR4 guide

catheter

• Volcano Verrata™

pressure wire

• Runthrough™ wire to

anchor guide

Page 33: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

IFR Assessment of the mid-RCA

Page 34: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

FFR with IV Adenosine

Page 35: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

Stent Deployment

• 4.0x15mm Resolute DES

Page 36: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

Results

Page 37: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

Why the discordance?

• Intact microvasculature needed to achieve minimal

resistance?

Page 38: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

Case 2

• 50yo with ESRD, HTN, HepB

• Prior PCI to RCA with BMS in 2004 (known occlusion of the stent in 2007)

• Prior PCI to LAD with Xience DES in 9/2013

• Presented with unstable angina

• Echo 3/2014: EF 56%, mild concentric LVH

Page 39: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

CFX

Page 40: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

Functional

Assessment

Page 41: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if
Page 42: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if
Page 43: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

Case 3

• 81yo with prior CAD admitted with USA and CHF.

• Known EF 30%.

• PCI to LCx and LAD in 2006

• Recent history of GI bleeding resulting in

discontinuation of Plavix.

Page 44: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

LAD

Page 45: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

LAD Assessment – iFR markedly +

Page 46: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

RCA

Page 47: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

Hemodynamic Assessment

of the RCA lesion

Page 48: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if
Page 49: Introduction to Instantaneous Wave-Free Ratio€¦ · DEFINE FLAIR Clinical Endpoints Study Objectives: • Determine safety and efficacy of PCI-guided iFR vs. FFR • Determine if

Conclusions – Part 2

• iFR (basal late diastolic) may be more accurate in

patients with tachycardia, LVH , anemia and elevated

LVEDP, ESRD – due to increased basal flow and

max’d out vasodilatory reserve +/- paradoxical

response to adenosine

• FFR is more accurate in patients with damaged or

diseased resistance vessels (ischemic

cardiomyopathy, prior infarct in terrritory and myopathic

supplied muscle) - need intact resistance vessels to

achieve minimal resistance

• Most other subsets have excellent correlation